Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27866680 | 0.89 | CA12 (0.59) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL627213 | 0.88 | CA12 (0.63) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL11861092 | 0.88 | CA12 (0.63) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL7437619 | 0.88 | CA12 (0.63) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL11868277 | 0.88 | CA12 (0.63) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL30295614 | 0.88 | CA12 (0.63) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL14174618 | 0.87 | CA12 (0.68) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL25111150 | 0.85 | CA12 (0.59) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL29602255 | 0.85 | ALDH1A1 (0.59) | CA12CA9ALDH1A1NPSR1KDM4E | |
| SCHEMBL1413232 | 0.85 | CA12 (0.70) | CA12CA9ALDH1A1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-0711180-A4 | FUNCTIONALIZED TRIPODAL LIGANDS FOR IMAGING APPLICATIONS | MALLINCKRODT MEDICAL INC (US) | 1996-11-27 | — | — | EP | disclosed |
| US-5565184-A | Functionalized tripodal ligands for x-ray & radioactive imaging applications | MALLINCKRODT MEDICAL, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0711180-A1 | FUNCTIONALIZED TRIPODAL LIGANDS FOR IMAGING APPLICATIONS | MALLINCKRODT MEDICAL, INC. (US) | 1996-05-15 | — | — | EP | disclosed |
| US-5405601-A | Functionalized tripodal ligands for imaging applications | MALLINCKRODT MEDICAL INC. (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1995001124-A1 | FUNCTIONALIZED TRIPODAL LIGANDS FOR IMAGING APPLICATIONS | MALLINCKRODT MEDICAL, INC. (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CA12 4067/4885CA9 1695/4885ALDH1A1 4285/4885 |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CA12 4067/4885CA9 1695/4885ALDH1A1 4285/4885 |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CA12 4067/4885CA9 1695/4885ALDH1A1 4285/4885 |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CA12 4067/4885CA9 1695/4885ALDH1A1 4285/4885 |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CA12 4067/4885CA9 1695/4885ALDH1A1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.